Abstract:Flaviviruses represent a significant global health threat and relatively few licensed vaccines exist to protect against them. Insect-specific flaviviruses (ISFVs) are incapable of replication in humans and have emerged as a novel and promising tool for flavivirus vaccine development. ISFV-based flavivirus vaccines have shown exceptional safety, immunogenicity, and efficacy, however, a detailed assessment of the correlates of protection and immune responses induced by these vaccines are still needed for vaccine optimization. Here, we explore the mechanisms of protective immunity induced by a previously created pre-clinical Zika virus (ZIKV) vaccine candidate, called Aripo/Zika (ARPV/ZIKV). In brief, immunocompromised IFN-αβR -/- mice passively immunized with ARPV/ZIKV immune sera experienced protection after lethal ZIKV challenge, although this protection was incomplete. ARPV/ZIKV-vaccinated IFN-αβR -/- mice depleted of CD4 + or CD8 + T-cells at the time of ZIKV challenge showed no morbidity or mortality. However, the adoptive transfer of ARPV/ZIKV-primed T-cells into recipient IFN-αβR -/- mice resulted in a two-day median increase in survival time compared to controls. Altogether, these results suggest that ARPV/ZIKV-induced protection is primarily mediated by neutralizing antibodies at the time of challenge and that T-cells may play a comparatively minor but cumulative role in the protection observed. Lastly, ARPV/ZIKV-vaccinated Tcra KO mice, which are deficient in T-cell responses, experienced significant mortality post-challenge. These results suggest that ARPV/ZIKV-induced cell-mediated responses are critical for development of protective immune responses at vaccination. Despite the strong focus on neutralizing antibody responses to novel flavivirus vaccine candidates, these results suggest that cell-mediated responses induced by ISFV-based vaccines remain important to overall protective responses. Conventional vaccine development platforms may involve trade-offs between vaccine safety and immunogenicity, but insect-specific viruses have recently emerged as a promising platform to overcome this challenge. We previously developed a preclinical Zika virus (ZIKV) vaccine candidate named Aripo/Zika virus (ARPV/ZIKV) based on a novel ISFV called Aripo virus (ARPV). Our previous studies demonstrated the high degree of safety as well as the single dose efficacy of ARPV/ZIKV. Here, we begin to elucidate the mechanisms of protection for this vaccine candidate. We demonstrate the dominant role of neutralizing antibodies in providing protection post-challenge, but also the importance of ARPV/ZIKV-induced T-cell responses in the priming phase of immunity. Overall, even high efficacy ISFV-based vaccine candidates such as ARPV/ZIKV may benefit from adjuvants or optimization strategies to increase protective T-cell responses. However, ARPV/ZIKV remains a promising ZIKV vaccine candidate, and contributes to the rapidly growing body of work that supports the potential of ISFVs as a new tool for protecting the health of the millions of people currently at risk of infection.

Study on the interaction between palladium(II)-lincomycin chelate and erythrosine by absorption, fluorescence and resonance Rayleigh scattering spectra and its analytical applications.

An immunoinformatics and structural vaccinology approach to design a novel and potent multi-epitope base vaccine targeting Zika virus

In silico construction of a multiepitope Zika virus vaccine using immunoinformatics tools

Rational design and production of a chimeric antigen targeting Zika virus that induces neutralizing antibodies in mice

Novel Non-Segmented Negative-Sense Rna Virus-Based Vaccine Platforms For Zika Virus

Preclinical Development of a Novel Zika Virus-like Particle Vaccine in Combination with Tetravalent Dengue Virus-like Particle Vaccines

Decision tree based ensemble machine learning model for the prediction of Zika virus T-cell epitopes as potential vaccine candidates

A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model

Exploring the immunogenicity of an insect-specific virus vectored Zika vaccine candidate

Targeting Yezo Virus Structural Proteins for Multi-Epitope Vaccine Design Using Immunoinformatics Approach

The Zika virus NS1 protein as a vaccine target

Humoral and T-cell-mediated responses to an insect-specific flavivirus-based Zika virus vaccine candidate

An In Silico Design of a Vaccine against All Serotypes of the Dengue Virus Based on Virtual Screening of B-Cell and T-Cell Epitopes

Understanding Zika Virus Stability and Developing a Chimeric Vaccine Through Functional Analysis

A Cognitive Modeling Approach - Does Tactical Breathing in a Psychomotor Task Influence Skill Development during Adaptive Instruction?

Enhanced Zika virus-like particle development using Baculovirus spp. constructs

Design of a novel epitope-based tetravalent subunit vaccine against dengue virus: an immunoinformatics approach

Log-ratio current for beam position monitoring

Critical Neutralizing Fragment Of Zika Virus Ediii Elicits Cross-Neutralization And Protection Against Divergent Zika Viruses

Immunogenicity and Efficacy of a Recombinant Human Adenovirus Type 5 Vaccine against Zika Virus

Nystatin Production by a Local Streptmyces sp. Isolated from Egyptian Soil